Standardization, validation, and comparative evaluation of a faster and high-performance test for quantification of yellow fever neutralizing antibodies

Simões, Marisol; da Silva, Stephanie Almeida; Lúcio, Kelly Araújo; de Oliveira Vieira, Renan; Schwarcz, Waleska Dias; de Lima, Sheila Maria Barbosa; Camacho, Luiz Antonio Bastos

doi:10.1016/j.jim.2023.113568

Cited by 3 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this context, the quantification of YF-specific neutralizing antibodies has been considered the gold standard. In the present study, the micro Focus Reduction Neutralization—Horseradish Peroxidase was used to quantify the YF-specific neutralizing antibodies titers and seropositivity rates, according to the standard protocol of μFRN-HRP described by Simões 12 . The results are shown in Fig.…”

Section: Resultsmentioning

confidence: 99%

“…Plasma samples stored at − 80 °C were thawed at 37 °C and pre-treated with ecteola-cellulose for heparin removal as previously described by Campi-Azevedo et al 30 , prior use for the YF-specific micro Focus Reduction Neutralization—Horseradish Peroxidase (μFRN-HRP). The μFRN-HRP test was carried out at Laboratório de Análise Imunomecular, Bio-Manguinhos (LANIM, FIOCRUZ-RJ, Brazil) to quantify the titers of YF-specific neutralizing antibodies and define the seropositivity rates according to Simões 12 , as follows: briefly, in 96-well plates, a mixture of ECT-treated plasma samples (1:6 to 1:1458) plus 17D-213/77 vaccine virus (70 PFU/well) was pre-incubated (2 h; 37 °C; 5% CO 2 ) and transferred to pre-formed Vero ATCC cell monolayer. Carboxymethylcellulose semisolid medium (2%) were added to each well and monolayers incubated for 48 h at 37 °C, 5% CO 2 .…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Comprehensive landscape of neutralizing antibody and cell-mediated response elicited by the 1/5 fractional dose of 17DD-YF primary vaccination in adults

Reis,

Costa-Rocha,

Abdala-Torres

et al. 2024

Sci Rep

Self Cite

View full text Add to dashboard Cite

The present study aimed at evaluating the YF-specific neutralizing antibody profile besides a multiparametric analysis of phenotypic/functional features of cell-mediated response elicited by the 1/5 fractional dose of 17DD-YF vaccine, administered as a single subcutaneous injection. The immunological parameters of each volunteer was monitored at two time points, referred as: before (Day 0) [Non-Vaccinated, NV(D0)] and after vaccination (Day 30–45) [Primary Vaccinees, PV(D30–45)]. Data demonstrated high levels of neutralizing antibodies for PV(D30–45) leading to a seropositivity rate of 93%. A broad increase of systemic soluble mediators with a mixed profile was also observed for PV(D30–45), with IFN-γ and TNF-α presenting the highest baseline fold changes. Integrative network mapping of soluble mediators showed increased correlation numbers in PV(D30–45) as compared to NV(D0) (532vs398). Moreover, PV(D30–45) exhibited increased levels of Terminal Effector (CD45RA+CCR7−) CD4+ and CD8+ T-cells and Non-Classical memory B-cells (IgD+CD27+). Dimensionality reduction of Mass Cytometry data further support these findings. A polyfunctional cytokine profile (TNF-α/IFN-γ/IL-10/IL-17/IL-2) of T and B-cells was observed upon in vitro antigen recall. Mapping and kinetics timeline of soluble mediator signatures for PV(D30–45) further confirmed the polyfunctional profile upon long-term in vitro culture, mediated by increased levels of IFN-γ and TNF-α along with decreased production of IL-10. These findings suggest novel insights of correlates of protection elicited by the 1/5 fractional dose of 17DD-YF vaccine.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Comprehensive landscape of neutralizing antibody and cell-mediated response elicited by the 1/5 fractional dose of 17DD-YF primary vaccination in adults

Reis,

Costa-Rocha,

Abdala-Torres

et al. 2024

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

Duration of post-vaccination immunity to yellow fever in volunteers ten years after a dose-response study – A complementary study

Vianna,

Noronha,

Camacho

et al. 2024

Vaccine

View full text Add to dashboard Cite

Humoral immunogenicity of primary yellow fever vaccination in infants and children: a systematic review, meta-analysis and meta-regression

Ferrara,

Losa,

Mantovani

et al. 2024

Journal of Travel Medicine

View full text Add to dashboard Cite

Background Vaccination plays a critical role in mitigating the burden associated with yellow fever (YF). However, there is a lack of comprehensive evidence on the humoral response to primary vaccination in the paediatric population, with several questions debated, including the response when the vaccine is administered at early ages, the effect of co-administration with other vaccines, the duration of immunity, and the use of fractional doses, among others. This study summarizes the existing evidence regarding the humoral response to primary YF vaccination in infants and children. Methods Studies on the humoral response to primary YF vaccination in children aged 12 years or younger were reviewed. The humoral vaccine response rate (VRR), i.e. the proportion of children who tested positive for vaccine-induced YF-specific neutralizing antibodies, was pooled through random-effects meta-analysis, and categorized based on the time elapsed since vaccination. Subgroup, meta-regression, and sensitivity analyses were performed. Results A total of 33 articles met the inclusion criteria, with all but one conducted in countries where YF is endemic. A total of 14 028 infants and children entered this systematic review. Within three months following vaccination, the pooled VRR was 91.9% (95%CI 89.8–93.9). A higher VRR observed after 17D-204 at the meta-regression analysis. No significant differences in immunogenicity outcomes were observed based on age, administration route, coadministration with other vaccines, or fractional dosing. Results also indicate a decline in VRR over time. Conclusions Primary YF vaccination effectively provides humoral immunity in paediatric population. However, humoral response declines over time, and this decline is observable after the first 18 months following vaccination. A differential response according to the vaccine substrain was also observed. This research has valuable implications for stimulating further research on the primary YF vaccination in infants and children, as well as for informing future policies.

show abstract

Standardization, validation, and comparative evaluation of a faster and high-performance test for quantification of yellow fever neutralizing antibodies

Cited by 3 publications

References 35 publications

Comprehensive landscape of neutralizing antibody and cell-mediated response elicited by the 1/5 fractional dose of 17DD-YF primary vaccination in adults

Comprehensive landscape of neutralizing antibody and cell-mediated response elicited by the 1/5 fractional dose of 17DD-YF primary vaccination in adults

Duration of post-vaccination immunity to yellow fever in volunteers ten years after a dose-response study – A complementary study

Humoral immunogenicity of primary yellow fever vaccination in infants and children: a systematic review, meta-analysis and meta-regression

Contact Info

Product

Resources

About